灯盏细辛对大鼠心肌缺血再灌注心律失常和细胞凋亡的影响  

Effect of Breviscapine on Arrhythmia and Myocyte Apoptosis Induced by Ischemia/Reperfusion

作　　者：王利果[1] 李树青[1] 

机构地区：[1]辽宁医学院附属第一医院

出　　处：《中西医结合心脑血管病杂志》2009年第1期52-54,共3页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

摘　　要：目的观察灯盏细辛(breviscapine)对大鼠缺血/再灌注(I/R)时室性心律失常和心肌细胞凋亡的影响,并与缬沙坦(val-sartan)比较其作用效果。方法40只大鼠随机分为假手术组(Sham组)、I/R组、灯盏细辛组(Bre组)和缬沙坦组(Val组),以穿线结扎左冠状动脉前降支制备大鼠心肌I/R模型,观察各组室性心动过速(VT)、血清肌酸激酶同工酶(CK-MB)、心肌组织总超氧化物歧化酶(TSOD)及丙二醛(MDA)变化。流式细胞凋亡法检测心肌凋亡细胞(AI)及免疫组化法检测心肌P53和细胞色素C(Cyt-C)蛋白表达。结果I/R组VT和CK-MB、MDA均高于Sham组,而TSOD低于Sham组;与I/R组比较,Bre组、Val组VT和、CK-MB、MDA均有降低,而TSOD活性增加。Bre组和Val组AI和P53、Cyt-C蛋白表达水平显著低于I/R组(P<0.01)。结论灯盏细辛可降低VT,下调P53、Cyt-C蛋白表达,抑制细胞凋亡,与缬沙坦有相近的保护效果。Objective To investigate the effect of Breviscapine （Bre） on ventricular arrhythmia and myocyte apoptosis induced by myocardial ischcmia/reperfusion （I/R）. Methods Forty Sprague - Dawley rats were divided into sham - operated group （Sham group）. I/R group,Breviscapine group （Bre group） and valsartan group （Val group） respectively. I/R injury was produced by occluding the left descending coronary artery （LCA） for 30 minutes and followed by reopening for 2 hours. ST -segment elevation and ventricular tachycardia （VT） were measured during the I/R period. The oxidative stress markers （TSOD, MDA） ,activities of creatine kinase isoenzyme - MB （CK - MB）. the number of the cells positive for P53 and Cyt -C and positive expression index （PEI） were determined after the experiment along with apoptotic index （AI） by Annexin - V - FITC/PI staining. Results Breviseapine and valsartan could decrease ventrieular arrhythmia. CK- MB,TSOD.MDA,AI,P53 and Cyt- C PEI in I/R group were higher than that in Breviscap group and val group （P〈0.01）. Conclusion Breviscapine could decrease the ventricular arrhythmia and inhibit the apoptosis by modulating the expression of P53 and Cyt -C protein induced by myocardial I/R, which with valsartan have similarly protective effects on I/R myocardium.

关 键 词：心肌缺血/再灌注损伤 灯盏细辛 室性心动过速 凋亡 

分 类 号：R541.7[医药卫生—心血管疾病]